Quest Diagnostics Inc (DGX) 78.90 $DGX
Shares of DGX Up 22.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 23, 1:45PM CDT
SmarTrend identified an Uptrend for Quest Diagnostics (NYSE
GX) on February 18th, 2016 at $65.35. In approximately 4 months, Quest Diagnostics has returned 22.59% as of today's recent price of $80.12.
DGX: 78.90 (-1.63)
Quest Diagnostics Rises 2.32% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Jun 22, 12:11PM CDT
Quest Diagnostics (NYSEGX) traded in a range yesterday that spanned from a low of $77.91 to a high of $80.11. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $78.38 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
DGX: 78.90 (-1.63)
Watch for Quest Diagnostics to Potentially Pullback After Gaining 2.32% Yesterday
Comtex SmarTrend(R) - Wed Jun 22, 12:09PM CDT
Quest Diagnostics (NYSEGX) traded in a range yesterday that spanned from a low of $77.91 to a high of $80.11. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $78.38 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
DGX: 78.90 (-1.63)
Quest Diagnostics to Relocate Headquarters to 500 Plaza Drive in Secaucus, NJ
PR Newswire - Mon Jun 20, 4:00AM CDT
Marcus Partners, a value-oriented real estate investor, announced today that Quest Diagnostics Incorporated, (NYSE: DGX), the world's leading provider of diagnostic information services, has signed a 130,200 square foot long term lease on the top four floors of 500 Plaza Drive in Secaucus, NJ, which will serve as the company's new headquarters location.
DGX: 78.90 (-1.63)
Look for Shares of Quest Diagnostics to Potentially Rebound after Yesterday's 1.74% Sell Off
Comtex SmarTrend(R) - Fri Jun 17, 1:48PM CDT
Quest Diagnostics (NYSEGX) traded in a range yesterday that spanned from a low of $75.20 to a high of $77.27. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $75.89 on volume of 780,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
DGX: 78.90 (-1.63)
Data Diagnostics Healthcare Technology Wins Two 2016 IT World Awards
PR Newswire - Thu Jun 09, 7:00AM CDT
Quest Diagnostics (NYSE: DGX) and Inovalon (NASDAQ: INOV) today announced that Data Diagnostics(TM), a point-of-care health analytics technology, has won two IT World Awards®. The solution earned a gold medal in the IT Products and Services for Healthcare category and a bronze medal for New Products and Services. Other companies to win awards in the New Products and Services category include Dell and Samsung. The Network Products Guide's IT World Awards are provided annually to honor achievement in all facets of the information technology industry.
DGX: 78.90 (-1.63), INOV: 17.42 (-0.32)
Quest Diagnostics to Relocate Corporate Headquarters, Consolidate Office Facilities, in New Jersey
PR Newswire - Mon Jun 06, 5:45AM CDT
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, will relocate its corporate headquarters from Madison, N.J. to Secaucus, N.J. when its lease expires in September 2017.
DGX: 78.90 (-1.63)
Fit Female College Athletes More Prone to Overreaching than Less Fit Ones, Putting Performance at Risk, Finds New Research Presented at American College of Sports Medicine Annual Meeting
PR Newswire - Thu Jun 02, 12:24PM CDT
Female college athletes at their highest pre-season fitness levels may be more susceptible to overreach in a team sport environment than less fit ones, according to original research being presented at the American College of Sports Medicine Annual (ACSM) Meeting.
DGX: 78.90 (-1.63)
Quest Diagnostics To Speak At The Goldman Sachs 37th Annual Global Healthcare Conference
PR Newswire - Thu Jun 02, 8:10AM CDT
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Goldman Sachs 2016 Global Healthcare Conference in Rancho Palos Verdes, California. Mark Guinan, the company's Senior Vice President and CFO, will discuss the company's vision, goals and five point strategy. The presentation is scheduled for Tuesday, June 7, 2016 at 11:40 a.m. Eastern Time.
DGX: 78.90 (-1.63)
One Year After Launch, BRCA Share(TM) Open Data Initiative Reveals New Findings on BRCA Gene Mutations Linked to Hereditary Breast and Ovarian Cancer Risk
PR Newswire - Wed Jun 01, 7:11AM CDT
BRCA Share, a public-private BRCA gene datashare initiative, today announced the public release of a large collection of new data on genetic variants in the BRCA1 and BRCA2 genes. Mutations of these genes raise the risk of breast, ovarian and other cancers. The findings are to be presented today at the 6th International Biennial Meeting of Human Variome Project Consortium (HVP6) held at UNESCO headquarters in Paris.
DGX: 78.90 (-1.63), LH: 129.62 (-1.56)
Quest Diagnostics and HCA's HealthONE System Partner to Deliver High-Value and Innovative Laboratory Services at Six Denver-Area HealthONE Hospitals
PR Newswire - Tue May 31, 5:45AM CDT
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and the HealthONE System of HCA Healthcare (NYSE: HCA) are teaming up to enhance the quality and value of diagnostic services to patients and their doctors through an agreement for Quest to manage in-patient laboratory operations for six Denver-area hospitals in the HealthONE system.
HCA: 76.72 (-3.03), DGX: 78.90 (-1.63)
Quest Diagnostics Launches Three Genetic Test Panels for Predicting Hereditary Cancer Risk
PR Newswire - Thu May 26, 10:54AM CDT
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the availability of three new cancer test services designed to provide clinically actionable insight into an individual's risk of developing hereditary forms of cancer. Part of the company's newly branded Quest Vantage(TM) cancer test menu, the tests and accompanying services are designed to provide physicians and patients with clinically actionable data and related support capabilities, including results interpretation, access to genetic counseling and prior authorization for health plan reimbursement.
DGX: 78.90 (-1.63)
Fitch Rates Quest's Senior Notes 'BBB'; Outlook Stable
BusinessWire - Mon May 23, 10:28AM CDT
Fitch Ratings has assigned a 'BBB' rating to Quest Diagnostics Inc.'s (Quest; NYSE: DGX) USD500 million 10-year senior notes offering. Fitch expects that the net proceeds from the offering will be used to repay outstanding indebtedness under the company's senior unsecured revolving credit facility and its secured receivables credit facility and for general corporate purposes. The Rating Outlook is Stable.
DGX: 78.90 (-1.63)
Quest Diagnostics Announces Proposed Senior Notes Offering
PR Newswire - Mon May 23, 7:42AM CDT
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it intends to offer $500,000,000 aggregate principal amount of senior notes in a public offering made under a shelf registration statement filed with the Securities and Exchange Commission, subject to market and other conditions.
DGX: 78.90 (-1.63)
Fitch Affirms Quest Diagnostics' Ratings at 'BBB'; Outlook Stable
BusinessWire - Fri May 20, 3:52PM CDT
Fitch Ratings has affirmed the ratings of Quest Diagnostics Inc. (Quest; NYSE: DGX) at 'BBB'. The Rating Outlook is Stable.
DGX: 78.90 (-1.63)
Quest Diagnostics (DGX) Divests Focus, Cuts Sales View
Zacks Equity Research - Zacks Investment Research - Thu May 19, 5:44AM CDT
Quest Diagnostics Inc. (DGX) has updated its outlook for 2016 following the completion of the sale of Focus Diagnostics Inc.
AFAM: 43.00 (unch), LHCG: 42.06 (-0.84), DGX: 78.90 (-1.63), HLS: 39.56 (-1.26)
Quest Diagnostics Declares Quarterly Cash Dividend
PR Newswire - Wed May 18, 8:00AM CDT
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.40 per share, payable on July 20, 2016 to shareholders of record of Quest Diagnostics common stock on July 6, 2016.
DGX: 78.90 (-1.63)
Quest Diagnostics Completes Effort to Refocus on Diagnostic Information Services; Updates 2016 Revenue Outlook
PR Newswire - Wed May 18, 5:45AM CDT
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has completed efforts to refocus its business on diagnostic information services following the completion of the sale of its Focus Diagnostics products business to DiaSorin S.p.A. for $300 million in cash.
DGX: 78.90 (-1.63)
Zika Test from Quest Diagnostics Authorized by the FDA for Emergency Use
PR Newswire - Thu Apr 28, 6:21PM CDT
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has received a U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for the Zika Virus RNA Qualitative Real-Time RT-PCR test (Zika RT-PCR test). The test was developed by the reference laboratory business of Quest's Focus Diagnostics, Inc., subsidiary. The proprietary molecular test is intended for the qualitative detection of RNA from the Zika virus in human serum specimens from certain individuals.
DGX: 78.90 (-1.63)
Quest Diagnostics (DGX) Q1 Earnings in Line, Volume Up
Zacks Equity Research - Zacks Investment Research - Thu Apr 21, 8:23AM CDT
Quest Diagnostics' (DGX) first-quarter 2016 adjusted earnings per share (EPS) of $1.12 came in line with the Zacks Consensus Estimate.
BSX: 22.37 (-0.60), AFAM: 43.00 (unch), DGX: 78.90 (-1.63), AMED: 49.13 (-1.78)
Shares of DGX Up 22.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 23, 1:45PM CDT
SmarTrend identified an Uptrend for Quest Diagnostics (NYSE
GX) on February 18th, 2016 at $65.35. In approximately 4 months, Quest Diagnostics has returned 22.59% as of today's recent price of $80.12. DGX: 78.90 (-1.63)
Quest Diagnostics Rises 2.32% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Jun 22, 12:11PM CDT
Quest Diagnostics (NYSE
GX) traded in a range yesterday that spanned from a low of $77.91 to a high of $80.11. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $78.38 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. DGX: 78.90 (-1.63)
Watch for Quest Diagnostics to Potentially Pullback After Gaining 2.32% Yesterday
Comtex SmarTrend(R) - Wed Jun 22, 12:09PM CDT
Quest Diagnostics (NYSE
GX) traded in a range yesterday that spanned from a low of $77.91 to a high of $80.11. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $78.38 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. DGX: 78.90 (-1.63)
Quest Diagnostics to Relocate Headquarters to 500 Plaza Drive in Secaucus, NJ
PR Newswire - Mon Jun 20, 4:00AM CDT
Marcus Partners, a value-oriented real estate investor, announced today that Quest Diagnostics Incorporated, (NYSE: DGX), the world's leading provider of diagnostic information services, has signed a 130,200 square foot long term lease on the top four floors of 500 Plaza Drive in Secaucus, NJ, which will serve as the company's new headquarters location.
DGX: 78.90 (-1.63)
Look for Shares of Quest Diagnostics to Potentially Rebound after Yesterday's 1.74% Sell Off
Comtex SmarTrend(R) - Fri Jun 17, 1:48PM CDT
Quest Diagnostics (NYSE
GX) traded in a range yesterday that spanned from a low of $75.20 to a high of $77.27. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $75.89 on volume of 780,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. DGX: 78.90 (-1.63)
Data Diagnostics Healthcare Technology Wins Two 2016 IT World Awards
PR Newswire - Thu Jun 09, 7:00AM CDT
Quest Diagnostics (NYSE: DGX) and Inovalon (NASDAQ: INOV) today announced that Data Diagnostics(TM), a point-of-care health analytics technology, has won two IT World Awards®. The solution earned a gold medal in the IT Products and Services for Healthcare category and a bronze medal for New Products and Services. Other companies to win awards in the New Products and Services category include Dell and Samsung. The Network Products Guide's IT World Awards are provided annually to honor achievement in all facets of the information technology industry.
DGX: 78.90 (-1.63), INOV: 17.42 (-0.32)
Quest Diagnostics to Relocate Corporate Headquarters, Consolidate Office Facilities, in New Jersey
PR Newswire - Mon Jun 06, 5:45AM CDT
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, will relocate its corporate headquarters from Madison, N.J. to Secaucus, N.J. when its lease expires in September 2017.
DGX: 78.90 (-1.63)
Fit Female College Athletes More Prone to Overreaching than Less Fit Ones, Putting Performance at Risk, Finds New Research Presented at American College of Sports Medicine Annual Meeting
PR Newswire - Thu Jun 02, 12:24PM CDT
Female college athletes at their highest pre-season fitness levels may be more susceptible to overreach in a team sport environment than less fit ones, according to original research being presented at the American College of Sports Medicine Annual (ACSM) Meeting.
DGX: 78.90 (-1.63)
Quest Diagnostics To Speak At The Goldman Sachs 37th Annual Global Healthcare Conference
PR Newswire - Thu Jun 02, 8:10AM CDT
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Goldman Sachs 2016 Global Healthcare Conference in Rancho Palos Verdes, California. Mark Guinan, the company's Senior Vice President and CFO, will discuss the company's vision, goals and five point strategy. The presentation is scheduled for Tuesday, June 7, 2016 at 11:40 a.m. Eastern Time.
DGX: 78.90 (-1.63)
One Year After Launch, BRCA Share(TM) Open Data Initiative Reveals New Findings on BRCA Gene Mutations Linked to Hereditary Breast and Ovarian Cancer Risk
PR Newswire - Wed Jun 01, 7:11AM CDT
BRCA Share, a public-private BRCA gene datashare initiative, today announced the public release of a large collection of new data on genetic variants in the BRCA1 and BRCA2 genes. Mutations of these genes raise the risk of breast, ovarian and other cancers. The findings are to be presented today at the 6th International Biennial Meeting of Human Variome Project Consortium (HVP6) held at UNESCO headquarters in Paris.
DGX: 78.90 (-1.63), LH: 129.62 (-1.56)
Quest Diagnostics and HCA's HealthONE System Partner to Deliver High-Value and Innovative Laboratory Services at Six Denver-Area HealthONE Hospitals
PR Newswire - Tue May 31, 5:45AM CDT
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and the HealthONE System of HCA Healthcare (NYSE: HCA) are teaming up to enhance the quality and value of diagnostic services to patients and their doctors through an agreement for Quest to manage in-patient laboratory operations for six Denver-area hospitals in the HealthONE system.
HCA: 76.72 (-3.03), DGX: 78.90 (-1.63)
Quest Diagnostics Launches Three Genetic Test Panels for Predicting Hereditary Cancer Risk
PR Newswire - Thu May 26, 10:54AM CDT
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the availability of three new cancer test services designed to provide clinically actionable insight into an individual's risk of developing hereditary forms of cancer. Part of the company's newly branded Quest Vantage(TM) cancer test menu, the tests and accompanying services are designed to provide physicians and patients with clinically actionable data and related support capabilities, including results interpretation, access to genetic counseling and prior authorization for health plan reimbursement.
DGX: 78.90 (-1.63)
Fitch Rates Quest's Senior Notes 'BBB'; Outlook Stable
BusinessWire - Mon May 23, 10:28AM CDT
Fitch Ratings has assigned a 'BBB' rating to Quest Diagnostics Inc.'s (Quest; NYSE: DGX) USD500 million 10-year senior notes offering. Fitch expects that the net proceeds from the offering will be used to repay outstanding indebtedness under the company's senior unsecured revolving credit facility and its secured receivables credit facility and for general corporate purposes. The Rating Outlook is Stable.
DGX: 78.90 (-1.63)
Quest Diagnostics Announces Proposed Senior Notes Offering
PR Newswire - Mon May 23, 7:42AM CDT
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it intends to offer $500,000,000 aggregate principal amount of senior notes in a public offering made under a shelf registration statement filed with the Securities and Exchange Commission, subject to market and other conditions.
DGX: 78.90 (-1.63)
Fitch Affirms Quest Diagnostics' Ratings at 'BBB'; Outlook Stable
BusinessWire - Fri May 20, 3:52PM CDT
Fitch Ratings has affirmed the ratings of Quest Diagnostics Inc. (Quest; NYSE: DGX) at 'BBB'. The Rating Outlook is Stable.
DGX: 78.90 (-1.63)
Quest Diagnostics (DGX) Divests Focus, Cuts Sales View
Zacks Equity Research - Zacks Investment Research - Thu May 19, 5:44AM CDT
Quest Diagnostics Inc. (DGX) has updated its outlook for 2016 following the completion of the sale of Focus Diagnostics Inc.
AFAM: 43.00 (unch), LHCG: 42.06 (-0.84), DGX: 78.90 (-1.63), HLS: 39.56 (-1.26)
Quest Diagnostics Declares Quarterly Cash Dividend
PR Newswire - Wed May 18, 8:00AM CDT
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.40 per share, payable on July 20, 2016 to shareholders of record of Quest Diagnostics common stock on July 6, 2016.
DGX: 78.90 (-1.63)
Quest Diagnostics Completes Effort to Refocus on Diagnostic Information Services; Updates 2016 Revenue Outlook
PR Newswire - Wed May 18, 5:45AM CDT
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has completed efforts to refocus its business on diagnostic information services following the completion of the sale of its Focus Diagnostics products business to DiaSorin S.p.A. for $300 million in cash.
DGX: 78.90 (-1.63)
Zika Test from Quest Diagnostics Authorized by the FDA for Emergency Use
PR Newswire - Thu Apr 28, 6:21PM CDT
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has received a U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for the Zika Virus RNA Qualitative Real-Time RT-PCR test (Zika RT-PCR test). The test was developed by the reference laboratory business of Quest's Focus Diagnostics, Inc., subsidiary. The proprietary molecular test is intended for the qualitative detection of RNA from the Zika virus in human serum specimens from certain individuals.
DGX: 78.90 (-1.63)
Quest Diagnostics (DGX) Q1 Earnings in Line, Volume Up
Zacks Equity Research - Zacks Investment Research - Thu Apr 21, 8:23AM CDT
Quest Diagnostics' (DGX) first-quarter 2016 adjusted earnings per share (EPS) of $1.12 came in line with the Zacks Consensus Estimate.
BSX: 22.37 (-0.60), AFAM: 43.00 (unch), DGX: 78.90 (-1.63), AMED: 49.13 (-1.78)
